These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 35751696)
1. Expert consensus on oncological [ Yu H; Gu Y; Fan W; Gao Y; Wang M; Zhu X; Wu Z; Liu J; Li B; Wu H; Cheng Z; Wang S; Zhang Y; Xu B; Li S; Shi H Eur Radiol; 2023 Jan; 33(1):615-626. PubMed ID: 35751696 [TBL] [Abstract][Full Text] [Related]
3. Are lesion features reproducible between Constantino CS; Oliveira FPM; Silva M; Oliveira C; Castanheira JC; Silva Â; Vaz SC; Vieira P; Costa DC Eur Radiol; 2021 May; 31(5):3071-3079. PubMed ID: 33125562 [TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
5. Mitigating SUV uncertainties using total body PET imaging. Smith CLC; Zwezerijnen GJC; den Hollander ME; Weijland J; Yaqub M; Boellaard R Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1070-1078. PubMed ID: 37953391 [TBL] [Abstract][Full Text] [Related]
6. The role of dynamic, static, and delayed total-body PET imaging in the detection and differential diagnosis of oncological lesions. Wu Y; Fu F; Meng N; Wang Z; Li X; Bai Y; Zhou Y; Liang D; Zheng H; Yang Y; Wang M; Sun T Cancer Imaging; 2024 Jan; 24(1):2. PubMed ID: 38167538 [TBL] [Abstract][Full Text] [Related]
7. The impact of Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508 [TBL] [Abstract][Full Text] [Related]
8. Ultralow-dose [ Tan H; Qi C; Cao Y; Cai D; Mao W; Yu H; Sui X; Liu G; Shi H Eur Radiol; 2023 Jul; 33(7):5017-5027. PubMed ID: 36688971 [TBL] [Abstract][Full Text] [Related]
14. The feasibility of ultralow-activity Lv J; Yin H; Yu H; Liu G; Shi H Ann Nucl Med; 2022 Oct; 36(10):887-896. PubMed ID: 35857172 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma. Westerland O; Amlani A; Kelly-Morland C; Fraczek M; Bailey K; Gleeson M; El-Najjar I; Streetly M; Bassett P; Cook GJR; Goh V; Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2558-2565. PubMed ID: 33469686 [TBL] [Abstract][Full Text] [Related]
16. Towards more accurate Priftakis D; Riaz S; Zumla A; Bomanji J Int J Infect Dis; 2020 Mar; 92S():S85-S90. PubMed ID: 32114199 [TBL] [Abstract][Full Text] [Related]
17. Whole-body Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514 [TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and background tissues. Povoski SP; Murrey DA; Smith SM; Martin EW; Hall NC BMC Cancer; 2014 Jun; 14():453. PubMed ID: 24942656 [TBL] [Abstract][Full Text] [Related]
19. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging. Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400 [TBL] [Abstract][Full Text] [Related]
20. Modification of [18F]-FDG PET/CT imaging protocols in obese oncology patients: A nationwide survey. Oliveira R; Figueiredo L; Costa P Radiography (Lond); 2023 Jan; 29(1):145-151. PubMed ID: 36370640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]